REPLIGEN CORP Lessee, Operating Lease, Liability, Undiscounted Excess Amount
REPLIGEN CORP (RGEN) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $25.18 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-02-26
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $25.18M.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $32.06M.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $32.59M.
- 2022-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $29.86M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $25.18M 10-K · filed 2026-02-26 |
| 2024-12-31 | $32.06M 10-K · filed 2025-03-14 |
| 2023-12-31 | $32.59M 10-K/A · filed 2024-11-18 |
| 2022-12-31 | $29.86M 10-K · filed 2023-02-22 |
| 2021-12-31 | $20.34M 10-K · filed 2022-02-17 |
| 2020-12-31 | $6.44M 10-K · filed 2021-02-24 |
| 2019-12-31 | $7.72M 10-K · filed 2020-02-26 |
| 2019-09-30 | $7.66M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $4.96M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $4.11M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |